A critical review of ferritin as a drug nanocarrier: Structure, properties, comparative advantages and challenges
Source abstract
Abstract
Abstract Ferritin stores and releases iron ions in mammals. It is globally important as a drug nanocarrier. This is because of its unique hollow-spherical structure, desirable stability and biological properties. Novel drug-loading approaches plus various functionalization approaches have been developed to improve ferritin in response to differing demands in disease treatments. Here, we critically review ferritin drug delivery and evaluate its diverse drug-loading and functionalization approaches, we: (1) Introduce basic structural and property information related to ferritin as a drug nanocarrier; (2) Contrast in detail the different means to load drugs and the selection of drug loading means; (3) Discuss multiple ferritin functionalization approaches, together with related advantages and potential risks; and, (4) Compare ferritin with alternative, commonly-used drug nanocarriers. We conclude that despite that no drugs based on ferritin are commercially available, the market potential for it is significant, and evaluate future research directions. Findings from this work will be of immediate benefit and interest to a wide range of researchers and manufacturers for drug delivery using ferritin.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Iron Metabolism and Disorders · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Four-fold channel-nicked human ferritin nanocages for active drug loading and pH-responsive drug release10.1002/anie.201800516 ↗
2. Structure, function, and evolution of ferritins10.1016/0162-0134(92)84062-R ↗
3. Nanoparticles in the clinic: An update10.1002/btm2.10143 ↗
4. Unraveling of the E-helices and disruption of 4-fold pores are associated with iron mishandling in a mutant ferritin causing neurodegeneration10.1074/jbc.M109.042986 ↗
5. The influence of the route of administration of gold nanoparticles on their tissue distribution and basic biochemical parameters: In vivo studies10.1016/j.pharep.2014.10.019 ↗
6. Protein cage nanostructure as drug delivery system: Magnifying glass on apoferritin10.1080/17425247.2017.1243528 ↗
7. Protein nanocages for self-triggered nuclear delivery of DNA-targeted chemotherapeutics in Cancer cells10.1016/j.jconrel.2014.10.002 ↗
8. Mesoporous silica nanoparticles in target drug delivery system: A review10.4103/2230-973X.160844 ↗
9. Apoferritin modified magnetic particles as doxorubicin carriers for anticancer drug delivery10.3390/ijms140713391 ↗
10. Everolimus nanoformulation in biological nanoparticles increases drug responsiveness in resistant and low-responsive breast cancer cell lines10.3390/pharmaceutics11080384 ↗
11. Production and characterization of functional recombinant hybrid heteropolymers of camel hepcidin and human ferritin H and L chains10.1093/protein/gzw066 ↗
12. Metal-organic framework-based nanomedicine platforms for drug delivery and molecular imaging10.1002/smll.201500802 ↗
13. Dendrimers and hyperbranched polymers10.1039/C5CS90049B ↗
14. Apoferritin nanocage for brain targeted doxorubicin delivery10.1021/acs.molpharmaceut.7b00341 ↗
15. TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer10.1038/s41419-020-2272-z ↗
16. The incorporation of GALA peptide into a protein cage for an acid-inducible molecular switch10.1016/j.biomaterials.2010.03.016 ↗
17. Targeted cancer cell delivery of arsenate as a reductively activated prodrug
18. L-Ferritin targets breast cancer stem cells and delivers therapeutic and imaging agents10.18632/oncotarget.10920 ↗
19. The crystal structure of a maxi/mini-ferritin chimera reveals guiding principles for the assembly of protein cages10.1021/acs.biochem.7b00312 ↗
20. Subunit interactions in horse spleen apoferritin. Dissociation by extremes of pH10.1042/bj1330289 ↗
21. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?10.1016/j.jconrel.2016.11.015 ↗
22. Application of gold nanoparticles in biomedical and drug delivery10.3109/21691401.2014.955107 ↗
23. Humanized archaeal ferritin as a tool for cell targeted delivery10.1039/C6NR07129E ↗
24. Apoferritin as an ubiquitous nanocarrier with excellent shelf life10.2147/IJN.S130267 ↗
25. Prostate-specific membrane antigen-targeted site-directed antibody-conjugated apoferritin nanovehicle favorably influences in vivo side effects of doxorubicin10.1038/s41598-018-26772-z ↗
26. Gold nanoparticle platforms as drug and biomacromolecule delivery systems10.1016/j.jconrel.2010.06.004 ↗
27. Polymeric nanoparticles: Promising platform for drug delivery10.1016/j.ijpharm.2017.06.052 ↗
28. Antibody-drug conjugates: Targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin10.1039/c3nr04268e ↗
29. Improved doxorubicin encapsulation and pharmacokinetics of ferritin-fusion protein nanocarriers bearing proline, serine, and alanine elements10.1021/acs.biomac.5b01446 ↗
30. The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity10.1016/j.jconrel.2018.02.025 ↗
31. Magnetoferritin nanoparticles for targeting and visualizing tumour tissues10.1038/nnano.2012.90 ↗
32. Ferritin nanocarrier traverses the blood brain barrier and kills glioma10.1021/acsnano.7b06969 ↗
33. Fenobody: a ferritin-displayed nanobody with high apparent affinity and half-life extension10.1021/acs.analchem.7b05217 ↗
34. Cisplatin binding sites in human H-chain ferritin10.1021/acs.inorgchem.7b01072 ↗
35. Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness10.1016/j.jconrel.2016.08.010 ↗
36. Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages10.3390/ijms151222960 ↗
37. Efficient expression of recombinant human heavy chain ferritin (FTH1) with modified peptides10.1016/j.pep.2016.06.003 ↗
38. Uranium-loaded apoferritin with antibodies attached: Molecular design for uranium neutron-capture therapy
39. Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development10.1016/j.nano.2013.11.003 ↗
40. Preparation, characterization, and pharmacokinetic study of a novel long-acting targeted paclitaxel liposome with antitumor activity10.2147/IJN.S228715 ↗
41. Exosomes as drug delivery vehicles for Parkinson’s disease therapy10.1016/j.jconrel.2015.03.033 ↗
42. Ferritin family proteins and their use in bionanotechnology10.1016/j.nbt.2014.12.006 ↗
43. Ferritin drug carrier (FDC) for tumor targeting therapy10.1016/j.jconrel.2019.09.002 ↗
44. Apoferritin applications in nanomedicine10.2217/nnm.14.119 ↗
45. Comparison of the three-dimensional structures of recombinant human H and horse L ferritins at high resolution10.1006/jmbi.1997.0970 ↗
46. The structure of apoferritin: Degradation into and molecular weight of subunits10.1016/S0022-2836(63)80087-X ↗
47. Development of a denaturation/renaturation-based production process for ferritin nanoparticles10.1002/bit.22140 ↗
48. Designed nanocage displaying ligand-specific peptide bunches for high affinity and biological activity10.1021/nn403184u ↗
49. Tumor fibroblast specific activation of a hybrid ferritin nanocage-based optical probe for tumor microenvironment imaging10.1002/smll.201300600 ↗
50. GRP78-targeted ferritin nanocaged ultra-high dose of doxorubicin for hepatocellular carcinoma therapy10.7150/thno.30867 ↗
51. Blood circulation-prolonging peptides for engineered nanoparticles identified via phage display10.1021/acs.nanolett.8b04007 ↗
52. Ferritin: A versatile building block for bionanotechnology10.1021/cr400011b ↗
53. Incorporation of thrombin cleavage peptide into a protein cage for constructing a protease-responsive multifunctional delivery nanoplatform10.1021/bm301339s ↗
54. PLGA: a unique polymer for drug delivery10.4155/tde.14.91 ↗
55. Ferritin-based drug delivery systems: Hybrid nanocarriers for vascular immunotargeting10.1016/j.jconrel.2018.02.042 ↗
56. A novel protein-based anticancer drug encapsulating nanosphere: Apoferritin-doxorubicin complex10.1166/jbn.2012.1406 ↗
57. Fluorescent ferritin nanoparticles and application to the aptamer sensor10.1021/ac200657s ↗
58. Designing peptide bunches on nanocage for bispecific or superaffinity targeting10.1021/acs.biomac.5b01753 ↗
59. Double-chambered ferritin platform: Dual-function payloads of cytotoxic peptides and fluorescent protein10.1021/acs.biomac.5b01134 ↗
60. pH-dependent structures of ferritin and apoferritin in solution: Disassembly and reassembly10.1021/bm200026v ↗
61. Ferritin for the clinician10.1016/j.blre.2008.08.001 ↗
62. Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin10.1016/j.biomaterials.2007.12.017 ↗
63. Ferritin and ferritin isoforms I: Structure-function relationships, synthesis, degradation and secretion10.1080/13813450701318583 ↗
64. An apoferritin-based drug delivery system for the tyrosine kinase inhibitor Gefitinib10.1002/adhm.201500389 ↗
65. Development of protein-cage-based delivery nanoplatforms by polyvalently displaying beta-cyclodextrins on the surface of ferritins through copper(I)-catalyzed azide/alkyne cycloaddition10.1002/mabi.201200178 ↗
66. Sur la cristallisation de la ferritine
67. Identification of the ferroxidase centre in ferritin10.1016/0014-5793(89)81040-3 ↗
68. Adaptations of nanoscale viruses and other protein cages for medical applications10.1016/j.nano.2006.07.009 ↗
69. Ferritin nanocage with intrinsically disordered proteins and affibody: A platform for tumor targeting with extended pharmacokinetics10.1016/j.jconrel.2017.08.014 ↗
70. Proteinticle engineering for accurate 3D diagnosis10.1021/nn404325t ↗
71. Magnetic enhancement of iron oxide nanoparticles encapsulated with poly(d,l-latide-co-glycolide)10.1016/j.colsurfa.2004.12.019 ↗
72. Engineered human ferritin nanoparticles for direct delivery of tumor antigens to lymph node and cancer immunotherapy10.1038/srep35182 ↗
73. Bioengineered protein-based nanocage for drug delivery10.1016/j.addr.2016.03.002 ↗
74. Targeted tumor delivery and controlled release of neuronal drugs with ferritin nanoparticles to regulate pancreatic cancer progression10.1016/j.jconrel.2016.03.023 ↗
75. Mutational analysis of the channel and loop sequences of human ferritin H-chain10.1042/bj2640381 ↗
76. Designing hydrogels for controlled drug delivery10.1038/natrevmats.2016.71 ↗
77. Scara5 is a ferritin receptor mediating non-transferrin iron delivery10.1016/j.devcel.2008.12.002 ↗
78. Comparison of two endogenous delivery agents in cancer therapy: Exosomes and ferritin10.1016/j.phrs.2016.05.006 ↗
79. Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting10.1002/smll.201200066 ↗
80. Nanoparticle ferritin-bound erastin and rapamycin: A nanodrug combining autophagy and ferroptosis for anticancer therapy10.1039/C9BM00653B ↗
81. Apoferritin nanocages with Au nanoshell coating as drug carrier for multistimuli-responsive drug release10.1016/j.msec.2018.10.060 ↗
82. H-ferritin–nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection
83. Bioengineered H-ferritin nanocages for quantitative imaging of vulnerable plaques in atherosclerosis10.1021/acsnano.8b04158 ↗
84. Chimeric ferritin nanocages for multiple function loading and multimodal imaging10.1021/nl104141g ↗
85. Hybrid ferritin nanoparticles as activatable probes for tumor imaging10.1002/anie.201006757 ↗
86. Denaturation of horse spleen ferritin in aqueous guanidinium chloride solutions10.1021/bi00761a026 ↗
87. Opening protein pores with chaotropes enhances Fe reduction and chelation of Fe from the ferritin biomineral10.1073/pnas.0636928100 ↗
88. Bio-inspired protein–gold nanoconstruct with core–void–shell structure: beyond a chemo drug carrier10.1039/C3TB20081G ↗
89. Smart nanoparticles for drug delivery application: Development of versatile nanocarrier platforms in biotechnology and nanomedicine10.1155/2019/3702518 ↗
90. Hyaluronic acid-conjugated apoferritin nanocages for lung cancer targeted drug delivery10.1039/C5BM00067J ↗
91. Isolation of point mutations that affect the folding of the H chain of human ferritin in E. Coli10.1002/j.1460-2075.1989.tb03411.x ↗
92. Ferritin nanovehicle for targeted delivery of cytochrome C to cancer cells10.1038/s41598-019-48037-z ↗
93. Polymer therapeutics and the EPR effect10.1080/1061186X.2017.1365878 ↗
94. Apoferritin-based nanomedicine platform for drug delivery: Equilibrium binding study of daunomycin with DNA10.1039/c0jm04321d ↗
95. Distinct stability of recombinant L and H subunits of human ferritin: Calorimetric and ANS binding studies10.1093/protein/11.5.377 ↗
96. Synthesis of inorganic nanophase materials in supramolecular protein cages10.1038/349684a0 ↗
97. Recent applications of PLGA based nanostructures in drug delivery10.1016/j.colsurfb.2017.07.038 ↗
98. Caged protein nanoparticles for drug delivery10.1016/j.copbio.2013.12.007 ↗
99. Ferritin-based anticancer metallodrug delivery: Crystallographic, analytical and cytotoxicity studies
100. Developing genetically engineered encapsulin protein cage nanoparticles as a targeted delivery nanoplatform10.1021/bm501066m ↗